Modeling the Mutational and Phenotypic Landscapes of Pelizaeus-Merzbacher Disease with Human iPSC-Derived Oligodendrocytes

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Modeling the Mutational and Phenotypic Landscapes of Pelizaeus-Merzbacher Disease with Human iPSC-Derived Oligodendrocytes. / Nevin, Zachary S.; Factor, Daniel C.; Karl, Robert T.; Douvaras, Panagiotis; Laukka, Jeremy; Windrem, Martha S.; Goldman, Steven A.; Fossati, Valentina; Hobson, Grace M.; Tesar, Paul J.

In: American Journal of Human Genetics, Vol. 100, No. 4, 06.04.2017, p. 617-634.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Nevin, ZS, Factor, DC, Karl, RT, Douvaras, P, Laukka, J, Windrem, MS, Goldman, SA, Fossati, V, Hobson, GM & Tesar, PJ 2017, 'Modeling the Mutational and Phenotypic Landscapes of Pelizaeus-Merzbacher Disease with Human iPSC-Derived Oligodendrocytes', American Journal of Human Genetics, vol. 100, no. 4, pp. 617-634. https://doi.org/10.1016/j.ajhg.2017.03.005

APA

Nevin, Z. S., Factor, D. C., Karl, R. T., Douvaras, P., Laukka, J., Windrem, M. S., Goldman, S. A., Fossati, V., Hobson, G. M., & Tesar, P. J. (2017). Modeling the Mutational and Phenotypic Landscapes of Pelizaeus-Merzbacher Disease with Human iPSC-Derived Oligodendrocytes. American Journal of Human Genetics, 100(4), 617-634. https://doi.org/10.1016/j.ajhg.2017.03.005

Vancouver

Nevin ZS, Factor DC, Karl RT, Douvaras P, Laukka J, Windrem MS et al. Modeling the Mutational and Phenotypic Landscapes of Pelizaeus-Merzbacher Disease with Human iPSC-Derived Oligodendrocytes. American Journal of Human Genetics. 2017 Apr 6;100(4):617-634. https://doi.org/10.1016/j.ajhg.2017.03.005

Author

Nevin, Zachary S. ; Factor, Daniel C. ; Karl, Robert T. ; Douvaras, Panagiotis ; Laukka, Jeremy ; Windrem, Martha S. ; Goldman, Steven A. ; Fossati, Valentina ; Hobson, Grace M. ; Tesar, Paul J. / Modeling the Mutational and Phenotypic Landscapes of Pelizaeus-Merzbacher Disease with Human iPSC-Derived Oligodendrocytes. In: American Journal of Human Genetics. 2017 ; Vol. 100, No. 4. pp. 617-634.

Bibtex

@article{5bece97f5462496b9b43e40e07f32d19,
title = "Modeling the Mutational and Phenotypic Landscapes of Pelizaeus-Merzbacher Disease with Human iPSC-Derived Oligodendrocytes",
abstract = "Pelizaeus-Merzbacher disease (PMD) is a pediatric disease of myelin in the central nervous system and manifests with a wide spectrum of clinical severities. Although PMD is a rare monogenic disease, hundreds of mutations in the X-linked myelin gene proteolipid protein 1 (PLP1) have been identified in humans. Attempts to identify a common pathogenic process underlying PMD have been complicated by an incomplete understanding of PLP1 dysfunction and limited access to primary human oligodendrocytes. To address this, we generated panels of human induced pluripotent stem cells (hiPSCs) and hiPSC-derived oligodendrocytes from 12 individuals with mutations spanning the genetic and clinical diversity of PMD-including point mutations and duplication, triplication, and deletion of PLP1-and developed an in vitro platform for molecular and cellular characterization of all 12 mutations simultaneously. We identified individual and shared defects in PLP1 mRNA expression and splicing, oligodendrocyte progenitor development, and oligodendrocyte morphology and capacity for myelination. These observations enabled classification of PMD subgroups by cell-intrinsic phenotypes and identified a subset of mutations for targeted testing of small-molecule modulators of the endoplasmic reticulum stress response, which improved both morphologic and myelination defects. Collectively, these data provide insights into the pathogeneses of a variety of PLP1 mutations and suggest that disparate etiologies of PMD could require specific treatment approaches for subsets of individuals. More broadly, this study demonstrates the versatility of a hiPSC-based panel spanning the mutational heterogeneity within a single disease and establishes a widely applicable platform for genotype-phenotype correlation and drug screening in any human myelin disorder.",
keywords = "Cell Culture Techniques, Child, Child, Preschool, Endoplasmic Reticulum Stress, Female, Humans, Induced Pluripotent Stem Cells, Male, Myelin Proteolipid Protein, Oligodendroglia, Pelizaeus-Merzbacher Disease, Journal Article",
author = "Nevin, {Zachary S.} and Factor, {Daniel C.} and Karl, {Robert T.} and Panagiotis Douvaras and Jeremy Laukka and Windrem, {Martha S.} and Goldman, {Steven A.} and Valentina Fossati and Hobson, {Grace M.} and Tesar, {Paul J.}",
note = "Copyright {\textcopyright} 2017 American Society of Human Genetics. Published by Elsevier Inc. All rights reserved.",
year = "2017",
month = apr,
day = "6",
doi = "10.1016/j.ajhg.2017.03.005",
language = "English",
volume = "100",
pages = "617--634",
journal = "American Journal of Human Genetics",
issn = "0002-9297",
publisher = "Cell Press",
number = "4",

}

RIS

TY - JOUR

T1 - Modeling the Mutational and Phenotypic Landscapes of Pelizaeus-Merzbacher Disease with Human iPSC-Derived Oligodendrocytes

AU - Nevin, Zachary S.

AU - Factor, Daniel C.

AU - Karl, Robert T.

AU - Douvaras, Panagiotis

AU - Laukka, Jeremy

AU - Windrem, Martha S.

AU - Goldman, Steven A.

AU - Fossati, Valentina

AU - Hobson, Grace M.

AU - Tesar, Paul J.

N1 - Copyright © 2017 American Society of Human Genetics. Published by Elsevier Inc. All rights reserved.

PY - 2017/4/6

Y1 - 2017/4/6

N2 - Pelizaeus-Merzbacher disease (PMD) is a pediatric disease of myelin in the central nervous system and manifests with a wide spectrum of clinical severities. Although PMD is a rare monogenic disease, hundreds of mutations in the X-linked myelin gene proteolipid protein 1 (PLP1) have been identified in humans. Attempts to identify a common pathogenic process underlying PMD have been complicated by an incomplete understanding of PLP1 dysfunction and limited access to primary human oligodendrocytes. To address this, we generated panels of human induced pluripotent stem cells (hiPSCs) and hiPSC-derived oligodendrocytes from 12 individuals with mutations spanning the genetic and clinical diversity of PMD-including point mutations and duplication, triplication, and deletion of PLP1-and developed an in vitro platform for molecular and cellular characterization of all 12 mutations simultaneously. We identified individual and shared defects in PLP1 mRNA expression and splicing, oligodendrocyte progenitor development, and oligodendrocyte morphology and capacity for myelination. These observations enabled classification of PMD subgroups by cell-intrinsic phenotypes and identified a subset of mutations for targeted testing of small-molecule modulators of the endoplasmic reticulum stress response, which improved both morphologic and myelination defects. Collectively, these data provide insights into the pathogeneses of a variety of PLP1 mutations and suggest that disparate etiologies of PMD could require specific treatment approaches for subsets of individuals. More broadly, this study demonstrates the versatility of a hiPSC-based panel spanning the mutational heterogeneity within a single disease and establishes a widely applicable platform for genotype-phenotype correlation and drug screening in any human myelin disorder.

AB - Pelizaeus-Merzbacher disease (PMD) is a pediatric disease of myelin in the central nervous system and manifests with a wide spectrum of clinical severities. Although PMD is a rare monogenic disease, hundreds of mutations in the X-linked myelin gene proteolipid protein 1 (PLP1) have been identified in humans. Attempts to identify a common pathogenic process underlying PMD have been complicated by an incomplete understanding of PLP1 dysfunction and limited access to primary human oligodendrocytes. To address this, we generated panels of human induced pluripotent stem cells (hiPSCs) and hiPSC-derived oligodendrocytes from 12 individuals with mutations spanning the genetic and clinical diversity of PMD-including point mutations and duplication, triplication, and deletion of PLP1-and developed an in vitro platform for molecular and cellular characterization of all 12 mutations simultaneously. We identified individual and shared defects in PLP1 mRNA expression and splicing, oligodendrocyte progenitor development, and oligodendrocyte morphology and capacity for myelination. These observations enabled classification of PMD subgroups by cell-intrinsic phenotypes and identified a subset of mutations for targeted testing of small-molecule modulators of the endoplasmic reticulum stress response, which improved both morphologic and myelination defects. Collectively, these data provide insights into the pathogeneses of a variety of PLP1 mutations and suggest that disparate etiologies of PMD could require specific treatment approaches for subsets of individuals. More broadly, this study demonstrates the versatility of a hiPSC-based panel spanning the mutational heterogeneity within a single disease and establishes a widely applicable platform for genotype-phenotype correlation and drug screening in any human myelin disorder.

KW - Cell Culture Techniques

KW - Child

KW - Child, Preschool

KW - Endoplasmic Reticulum Stress

KW - Female

KW - Humans

KW - Induced Pluripotent Stem Cells

KW - Male

KW - Myelin Proteolipid Protein

KW - Oligodendroglia

KW - Pelizaeus-Merzbacher Disease

KW - Journal Article

U2 - 10.1016/j.ajhg.2017.03.005

DO - 10.1016/j.ajhg.2017.03.005

M3 - Journal article

C2 - 28366443

VL - 100

SP - 617

EP - 634

JO - American Journal of Human Genetics

JF - American Journal of Human Genetics

SN - 0002-9297

IS - 4

ER -

ID: 185946430